Premium
Prolonged disease‐free survival in relapsed/refractory low‐grade lymphoma treated with fludarabine: a report of four cases
Author(s) -
Alexander Sternberg,
Estella Matutes,
Sally Killick,
Andrew Wotherspoon,
Daniel Catovsky
Publication year - 1998
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1998.00792.x
Subject(s) - medicine , fludarabine , follicular lymphoma , refractory (planetary science) , chlorambucil , lymphoma , chemoimmunotherapy , gastroenterology , stage (stratigraphy) , transplantation , surgery , oncology , chemotherapy , cyclophosphamide , rituximab , paleontology , physics , astrobiology , biology
We report four patients with relapsed or refractory follicular (three) and lymphoplasmacytic (one) lymphoma who achieved complete remission (CR) with fludarabine (FDR) lasting from 3.2 to 6 years. One had stage III and three stage IV and were resistant to chlorambucil and/or anthracycline. FDR was well tolerated, the only complication being herpes zoster infection in three patients, which was controlled with aciclovir. One patient developed a gastric MALT lymphoma from a different clone than the follicular lymphoma. In conclusion, some patients with refractory low‐grade lymphoma achieve long‐term CR with FDR; therefore this agent may be considered as alternative to stem‐cell transplantation.